These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 37619930)

  • 1. Steatotic liver disease as a new nomenclature for NAFLD from the perspectives of the MENA region: One size fits all this time.
    El-Kassas M; Alswat K;
    J Hepatol; 2024 Feb; 80(2):e66-e68. PubMed ID: 37619930
    [No Abstract]   [Full Text] [Related]  

  • 2. Paediatric steatotic liver disease has unique characteristics: A multisociety statement endorsing the new nomenclature.
    ; ; ; ; ; ; ;
    J Pediatr Gastroenterol Nutr; 2024 May; 78(5):1190-1196. PubMed ID: 38529849
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Global survey of stigma among physicians and patients with nonalcoholic fatty liver disease.
    Younossi ZM; Alqahtani SA; Alswat K; Yilmaz Y; Keklikkiran C; Funuyet-Salas J; Romero-Gómez M; Fan JG; Zheng MH; El-Kassas M; Castera L; Liu CJ; Wai-Sun Wong V; Zelber-Sagi S; Allen AM; Lam B; Treeprasertsuk S; Hameed S; Takahashi H; Kawaguchi T; Schattenberg JM; Duseja A; Newsome PN; Francque S; Spearman CW; Castellanos Fernández MI; Burra P; Roberts SK; Chan WK; Arrese M; Silva M; Rinella M; Singal AK; Gordon S; Fuchs M; Alkhouri N; Cusi K; Loomba R; Ranagan J; Eskridge W; Kautz A; Ong JP; Kugelmas M; Eguchi Y; Diago M; Yu ML; Gerber L; Fornaresio L; Nader F; Henry L; Racila A; Golabi P; Stepanova M; Carrieri P; Lazarus JV;
    J Hepatol; 2024 Mar; 80(3):419-430. PubMed ID: 37984709
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Critical appraisal of metabolic dysfunction-associated steatotic liver disease: Implication of Janus-faced modernity.
    Kim GA; Moon JH; Kim W
    Clin Mol Hepatol; 2023 Oct; 29(4):831-843. PubMed ID: 37634892
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Metabolic dysfunction-associated steatotic liver disease: Time to get familiar with the new name for NAFLD.
    Podszun MC
    Nutr Res; 2024 Jun; 126():11-13. PubMed ID: 38583389
    [No Abstract]   [Full Text] [Related]  

  • 6. Burden of non-alcoholic fatty liver disease in Asia, the Middle East and North Africa: Data from Global Burden of Disease 2009-2019.
    Golabi P; Paik JM; AlQahtani S; Younossi Y; Tuncer G; Younossi ZM
    J Hepatol; 2021 Oct; 75(4):795-809. PubMed ID: 34081959
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Is it time to change NAFLD and NASH nomenclature?
    Bellentani S; Tiribelli C
    Lancet Gastroenterol Hepatol; 2017 Aug; 2(8):547-548. PubMed ID: 28691681
    [No Abstract]   [Full Text] [Related]  

  • 8. The new hepatic steatosis nomenclature. No more NAFLD!
    Castro-Narro GE; Rinella ME
    Rev Gastroenterol Mex (Engl Ed); 2024; 89(2):312-313. PubMed ID: 38789309
    [No Abstract]   [Full Text] [Related]  

  • 9. [Effect of the nomenclature of non-alcoholic fatty liver disease on diagnosis and treatment of fatty liver disease concomitant with other liver diseases].
    Chen L; Jiang LN; Zhao JM
    Zhonghua Gan Zang Bing Za Zhi; 2023 Aug; 31(8):805-809. PubMed ID: 37723061
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [NASH: new terminology and what else is new in 2020].
    Spahr L; Giostra E; Negro F; Goossens N
    Rev Med Suisse; 2020 Sep; 16(704):1544-1547. PubMed ID: 32880109
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PAKISTAN SOCIETY OF HEPATOLOGY (PSH) POSITION STATEMENT: RENAMING NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD) TO STEATOTIC LIVER DISEASE (SLD), ENDORSEMENT OF NEW MULTI-SOCIETY NOMENCLATURE.
    Ali Z; Riaz M; Alam A; Faroqi JI
    J Ayub Med Coll Abbottabad; 2023; 35(4):700-702. PubMed ID: 38406965
    [No Abstract]   [Full Text] [Related]  

  • 12. A multisociety Delphi consensus statement on new fatty liver disease nomenclature.
    Rinella ME; Lazarus JV; Ratziu V; Francque SM; Sanyal AJ; Kanwal F; Romero D; Abdelmalek MF; Anstee QM; Arab JP; Arrese M; Bataller R; Beuers U; Boursier J; Bugianesi E; Byrne CD; Castro Narro GE; Chowdhury A; Cortez-Pinto H; Cryer DR; Cusi K; El-Kassas M; Klein S; Eskridge W; Fan J; Gawrieh S; Guy CD; Harrison SA; Kim SU; Koot BG; Korenjak M; Kowdley KV; Lacaille F; Loomba R; Mitchell-Thain R; Morgan TR; Powell EE; Roden M; Romero-Gómez M; Silva M; Singh SP; Sookoian SC; Spearman CW; Tiniakos D; Valenti L; Vos MB; Wong VW; Xanthakos S; Yilmaz Y; Younossi Z; Hobbs A; Villota-Rivas M; Newsome PN;
    J Hepatol; 2023 Dec; 79(6):1542-1556. PubMed ID: 37364790
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Non-alcoholic fatty liver disease to metabolic dysfunction-associated fatty liver disease: Conceptual changes for clinicians, researchers and patients.
    Lin SZ; Chen YW; Fan JG
    J Dig Dis; 2020 Nov; 21(11):604-609. PubMed ID: 32975050
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phosphatase and tensin homolog is a differential diagnostic marker between nonalcoholic and alcoholic fatty liver disease.
    Sanchez-Pareja A; Clément S; Peyrou M; Spahr L; Negro F; Rubbia-Brandt L; Foti M
    World J Gastroenterol; 2016 Apr; 22(14):3735-45. PubMed ID: 27076758
    [TBL] [Abstract][Full Text] [Related]  

  • 15. From NAFLD to MASLD: implications of the new nomenclature for preclinical and clinical research.
    Hsu CL; Loomba R
    Nat Metab; 2024 Apr; 6(4):600-602. PubMed ID: 38383845
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MAFLD: A Consensus-Driven Proposed Nomenclature for Metabolic Associated Fatty Liver Disease.
    Eslam M; Sanyal AJ; George J;
    Gastroenterology; 2020 May; 158(7):1999-2014.e1. PubMed ID: 32044314
    [TBL] [Abstract][Full Text] [Related]  

  • 17. From non-alcoholic fatty liver disease (NAFLD) to metabolic-associated fatty liver disease (MAFLD): A journey over 40 years.
    Kuchay MS; Misra A
    Diabetes Metab Syndr; 2020; 14(4):695-696. PubMed ID: 32442920
    [No Abstract]   [Full Text] [Related]  

  • 18. Paediatric fatty liver disease (PeFLD): All is not NAFLD - Pathophysiological insights and approach to management.
    Hegarty R; Deheragoda M; Fitzpatrick E; Dhawan A
    J Hepatol; 2018 Jun; 68(6):1286-1299. PubMed ID: 29471012
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A multisociety Delphi consensus statement on new fatty liver disease nomenclature.
    Rinella ME; Lazarus JV; Ratziu V; Francque SM; Sanyal AJ; Kanwal F; Romero D; Abdelmalek MF; Anstee QM; Arab JP; Arrese M; Bataller R; Beuers U; Boursier J; Bugianesi E; Byrne CD; Narro GEC; Chowdhury A; Cortez-Pinto H; Cryer DR; Cusi K; El-Kassas M; Klein S; Eskridge W; Fan J; Gawrieh S; Guy CD; Harrison SA; Kim SU; Koot BG; Korenjak M; Kowdley KV; Lacaille F; Loomba R; Mitchell-Thain R; Morgan TR; Powell EE; Roden M; Romero-Gómez M; Silva M; Singh SP; Sookoian SC; Spearman CW; Tiniakos D; Valenti L; Vos MB; Wong VW; Xanthakos S; Yilmaz Y; Younossi Z; Hobbs A; Villota-Rivas M; Newsome PN;
    Ann Hepatol; 2024; 29(1):101133. PubMed ID: 37364816
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A multisociety Delphi consensus statement on new fatty liver disease nomenclature.
    Rinella ME; Lazarus JV; Ratziu V; Francque SM; Sanyal AJ; Kanwal F; Romero D; Abdelmalek MF; Anstee QM; Arab JP; Arrese M; Bataller R; Beuers U; Boursier J; Bugianesi E; Byrne CD; Castro Narro GE; Chowdhury A; Cortez-Pinto H; Cryer DR; Cusi K; El-Kassas M; Klein S; Eskridge W; Fan J; Gawrieh S; Guy CD; Harrison SA; Kim SU; Koot BG; Korenjak M; Kowdley KV; Lacaille F; Loomba R; Mitchell-Thain R; Morgan TR; Powell EE; Roden M; Romero-Gómez M; Silva M; Singh SP; Sookoian SC; Spearman CW; Tiniakos D; Valenti L; Vos MB; Wong VW; Xanthakos S; Yilmaz Y; Younossi Z; Hobbs A; Villota-Rivas M; Newsome PN;
    Hepatology; 2023 Dec; 78(6):1966-1986. PubMed ID: 37363821
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.